New drug cocktail aims to wipe out Hard-to-Treat leukemia and MDS
NCT ID NCT07153497
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding olutasidenib to standard treatments helps people with IDH1-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For AML, the standard is a chemotherapy pill plus venetoclax; for higher-risk MDS, it's the chemotherapy pill alone. The study will enroll 132 people and measure how many achieve complete remission or improved blood counts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olutasidenib (a targeted drug that blocks the mutated IDH1 protein), decitabine-cedazuridine (ASTX727, a chemotherapy pill), and venetoclax (a targeted drug that helps kill cancer cells)
- What this could lead to
- If successful, this combination could become a new standard treatment for people with IDH1-mutant AML or MDS, leading to higher remission rates and better blood counts.
- What could go wrong
- This is a phase 2 trial, so it is still early. The added drug may not improve outcomes enough, or side effects could outweigh benefits. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can trained immune cells stop blood cancer relapse?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?